# Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

> **NCT07674771** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Prostate Cancer
- Castration Sensitive Prostate Cancer
- Metastatic Prostate Cancer
- Adaptive Radiotherapy

## Interventions

- **DRUG:** Drug: 68-Ga PSMA11
- **RADIATION:** Adaptive stereotactic ablative radiotherapy (SABR)
- **DRUG:** 68Ga-PSMA-11
- **RADIATION:** Adaptive stereotactive ablative radiotherapy (SABR)

## Key facts

- **NCT ID:** NCT07674771
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2029-06-15
- **Final completion:** 2029-06-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07674771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07674771, "Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07674771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*